Australian CIDP National Registry: Dissecting Phenotypes and Immunoglobulin Usage Requirements

Project Member(s): Street, D., Goodall, S.

Funding or Partner Organisation: Commonwealth Department of Health and Aged Care (MRFF - Optimising the Clinical Use of Immunoglobulins - Stream 4 2021)
Commonwealth Department of Health and Aged Care (MRFF - Optimising the Clinical Use of Immunoglobulins - Stream 4 2021)

Start year: 2022

Summary: This project addresses the objectives outlined in section 1.3 of the 2021 Optimising the Clinical Use of Immunoglobulin Grant Opportunity Guidelines, specifically under Stream 4: to build the evidence-base to inform the cost-effective clinical use of immunoglobulin in Australia. Chronic inflammatory demyelinating polyneuropathy (CIDP) is the second most common indication for immunoglobulin (Ig) use in Australia. There are significant gaps in our understanding of CIDP in Australia, highlighted by the recent Australian Government Medical Services Advisory Committee (MSAC) Review of Ig for CIDP which indicated discrepancy between the expected prevalence of CIDP in Australia compared to Ig usage. This project will establish an Australian CIDP National Registry to track, collect and evaluate patient outcomes in real world settings, providing essential Australian-specific data to guide future management approaches. This data is critical to inform cost-effectiveness and sustainability of Ig use and determine how best to enhance clinical outcomes for patients. This research will directly inform policy development promoting the efficient and effective use of Ig products.

FOR Codes: Public health (excl. specific population health), Health economics